Web Exclusives
The US Food and Drug Administration (FDA) today approved Yondelis (trabectedin), a chemotherapy, for the treatment of specific soft tissue sarcomas (STS)—liposarcoma and leiomyosarcoma—that cannot be removed by surgery (unresectable) or is advanced (metastatic).
The US Food and Drug Administration (FDA) granted accelerated approval for Keytruda (pembrolizumab) to treat patients with advanced (metastatic) non–small-cell lung cancer (NSCLC) whose disease has progressed after other treatments, and with tumors that express a protein called PD-L1.
On September 30, 2015, the US Food and Drug Administration (FDA) granted accelerated approval to nivolumab (Opdivo Injection, Bristol-Myers Squibb Company) in combination with ipilimumab for the treatment of patients with BRAF V600 wild-type, unresectable or metastatic melanoma.
The National Prescription Drug Take-Back addresses a vital public safety and public health issue. Many patients are not aware that the medicines in their cabinets are highly susceptible to diversion, misuse, and abuse.
Adherence to certain strategies can aid pharmacists in successful navigation of our increasingly collaborative healthcare landscape.
At the National Comprehensive Cancer Network 20th Annual Conference, Mario E. Lacouture, MD, presented some clinical pearls that can guide the management of dermatologic toxicities.
Novel therapies for patients with multiple myeloma (MM) continue to show improved outcomes for a population that as little as 8 years ago had few options.
Most of the illnesses that are encountered in medicine are incurable. Diabetes and heart disease are 2 of the common, chronic, and incurable health conditions that require diligent monitoring.
The past decade has given us several breakthrough treatment options for a complex and serious malignancy, multiple myeloma (MM).
Multiple myeloma (MM) accounts for 10% to 15% of all hematologic malignancies, and is the cause of 20% of the deaths that result from blood and bone cancers.